

MT2023-41: A Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Idecabtagene Vicleucel with Lenalidomide Maintenance Versus Lenalidomide Maintenance Therapy Alone in Adult Participants with Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMA-9).

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- new diagnosis of Multiple Myeloma - received induction therapy followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT) - unable to do physically strenuous activity but walking and able to carry out work of a light or sedentary nature, e.g., light house work, office work - see link to clinicaltrials.gov for complete inclusion and exclusion criteria

Exclusion Criteria:

- central nervous system involvement with myeloma - uncontrolled fungal, bacterial, viral, or other infection - history of primary immunodeficiency

Conditions & Interventions

Conditions:

Cancer

Keywords:

Clinics and Surgery Center (CSC), Multiple Myeloma

More Information

Description: This study is to understand if Idecabtagene Vicleucel (ide-cel), when given with a standard anti-myeloma maintenance therapy called lenalidomide (LEN), will be safe and more effective, when compared to LEN given alone.

Study Contact: Daniel O'Leary - dholeary@umn.edu

Principal Investigator: Daniel O'Leary

IRB

Number: STUDY00021712

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.